All AbMole products are for research use only, cannot be used for human consumption.
SU5402 is a potent and selective small molecular vascular endothelial growth factor receptor (VEGFR) and fibroblast growth factor receptor (FGFR) inhibitor. SU5402 inhibits embryonic left-right determination and exhibits potent anticancer activity in vitro and in vivo.
Stem Cell Reports. 2017 May 9;8(5):1312-1328.
2i Maintains a Naive Ground State in ESCs through Two Distinct Epigenetic Mechanisms
SU5402 purchased from AbMole
. su5402, figure1 ..jpg) |
Source | Stem Cell Reports (2017). SU5402, Figure1 . (AbMole Bioscience) |
| Method | ||
| Cell Lines | The mouse ESC lines J1 (ATCC SCRC-1010), CCE, and Jmjd2c KO | |
| Concentrations | 10 μM | |
| Incubation Time | ||
| Results | FGFR inhibition (FGFRi) by SU5402 had little effect compared with LIF (Figure 1A). A two-inhibitor combination (PD0325901 and CHIR99021) and a threeinhibitor combination (PD0325901, CHIR99021, and SU5402) produced robust AP staining of ESCs with a compact colony morphology. |
| Cell Experiment | |
|---|---|
| Cell lines | KMS11, UTMC-2, LP1, OPM1, OPM2, KHM11, JJN3, RPMI8226, EJM, K620, H929, U266 and OCI-My5 cell lines |
| Preparation method | KMS11 (provided by MasayoshiNamba), UTMC-2, LP1, OPM1, OPM2, KHM11, JJN3, RPMI8226, EJM, K620, H929 (provided by Leif Bergsagel), U266 and OCI-My5 (provided by Robert Hawley) were grown in Iscove’s modified Dulbecco’s medium (IMDM) supplemented with 10% fetal calf serum (FCS) and 1% Gibco antimycotic/antibiotic (Invitrogen Canada, Ontario, Canada). For proliferation assays, cells were washed and plated in triplicate in IMDM plus 5% FCS and incubated with various concentrations of SU5402. Cells were then analysed by MTT [3-(4,5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide] assay (Boehringer Mannheim, Mannheim, Germany) according to the manufacturer’s protocol. |
| Concentrations | 0, 2,10µM |
| Incubation time | 48 h |
| Animal Experiment | |
|---|---|
| Animal models | Spinal cords lesions of zebrafish |
| Formulation | DMSO |
| Dosages | 1 μl of 5 μg/μl |
| Administration | injection |
| Molecular Weight | 296.32 |
| Formula | C17H16N2O3 |
| CAS Number | 215543-92-3 |
| Solubility (25°C) | DMSO 30 mg/mL |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
| Related VEGFR/PDGFR Products |
|---|
| ABT-869
ABT-869 (Linifanib) is an ATP-competitive, multi-targeted RTK inhibitor that is completely effective against all members of VEGFR and PDGFR. |
| Tivozanib (AV-951)
Tivozanib (AV-951) is a potent VEGFR-1, 2 and 3, c-Kit and PDGFR inhibitor with IC50 of 0.21, 0.16, 0.24, 1.63 and 1.72 nM respectively. |
| Axitinib
Axitinib (AG013736) inhibits multiple targets including VEGFR, PDGFR and cKit. |
| Regorafenib
Regorafenib (BAY 73-4506) is a novel oral multikinase inhibitor of c-KIT, VEGFR2, B-Raf with IC50s of 17, 40 and 69 nM respectively. |
| Nintedanib
Nintedanib (BIBF1120) is a novel, potent triple angiokinase inhibitor for VEGFR1/2/3, FGFR1/2/3 and PDGFRα/β with IC50s of 34 nM/13 nM/13 nM, 69 nM/37 nM/108 nM and 59 nM/65 nM, respectively. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2026 AbMole BioScience. All Rights Reserved.
